Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed

BACKGROUND: It has not been clearly established whether second-generation tyrosine kinase inhibitors actually improve the survival of patients with chronic myeloid leukemia in chronic phase who are given nilotinib or dasatinib therapy after treatment failure with imatinib. DESIGN AND METHODS: To add...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Ibrahim, Amr R., Clark, Richard E., Holyoake, Tessa L., Byrne, Jenny, Shepherd, Pat, Apperley, Jane F., Milojkovic, Dragana, Szydlo, Richard, Goldman, John, Marin, David
Formato: Artigo
Idioma:Inglês
Publicado em: Ferrata Storti Foundation 2011
Assuntos:
Original Articles
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3232259/
https://ncbi.nlm.nih.gov/pubmed/21859733
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2011.049759
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados